Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT07349537
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RMC-5127 — DRUG
    oral tablets
  • daraxonrasib — DRUG
    oral tablets
  • cetuximab — DRUG
    IV infusion

Study Details

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

Key Dates

Start date
Jan 8, 2026
Status verified
May 2026
Primary completion
Apr 30, 2028
Completion
Oct 31, 2028

Study Design

Enrollment
574 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: RMC-5127 Monotherapy
    Dose Escalation and Dose Expansion
  • Experimental: Arm B: RMC-5127 + Daraxonrasib Combination
    Dose Escalation and Dose Expansion
  • Experimental: Arm C: RMC-5127 + Cetuximab Combination
    Dose Escalation and Dose Expansion

Primary Outcome Measure

Number of patients with adverse events (AEs) [ Time Frame: Up to approximately 3 years ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
START MidwestGrand RapidsMichigan49546
616-954-5554
NEXT - DallasDallasTexas75039
NEXT TXReferrels
972-893-8800
NEXTSan AntonioTexas78229
Jordan Georg
210-580-9521
START - San AntonioSan AntonioTexas78229
Isabel Jimenez
210-593-5265
NEXT - VirginiaFairfaxVirginia22031
Paolo Umayam
703-783-4546

Find similar trials in Grand Rapids, MI

Related Studies